NCT05854498View on ClinicalTrials.gov

Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

October 13, 2023

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

Liposomal irinotecan

50mg/m2 IV on days 1 and 15

DRUG

TAS102

35mg/m2 PO BID on days 1-5 and 15-19

DRUG

Bevacizumab

5mg/kg IV on days 1 and 15

Trial Locations (1)

52792

University of Wisconsin Carbone Cancer Center, Madison

Sponsors

Collaborators (1)

Ipsen
All Listed Sponsors
collaborator

Ipsen

INDUSTRY

lead

University of Wisconsin, Madison

OTHER

NCT05854498 - Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter